{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:40:06Z","timestamp":1744152006448,"version":"3.40.3"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s11908-014-0447-4","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T22:49:53Z","timestamp":1416005393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Intravenous Immunoglobulin in Critically Ill Patients"],"prefix":"10.1007","volume":"16","author":[{"given":"Summer","family":"Donovan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo M. L.","family":"Bearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,12]]},"reference":[{"unstructured":"American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. Pickering LK, ed. 29th ed. Elk Grove Village, IL; 2012:56-62.","key":"447_CR1"},{"key":"447_CR2","first-page":"133","volume":"15","author":"K Kawada","year":"1987","unstructured":"Kawada K, Terasaki PI. Evidence for immunosuppression by high dose gammaglobulin. Exp Hematol. 1987;15:133\u20136.","journal-title":"Exp Hematol"},{"key":"447_CR3","first-page":"697","volume":"53","author":"T Tsubakio","year":"1983","unstructured":"Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983;53:697.","journal-title":"Clin Exp Immunol"},{"key":"447_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2141.1985.tb07417.x","volume":"60","author":"JF Delfraissy","year":"1985","unstructured":"Delfraissy JF, Tchernia G, Laurian Y, et al. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985;60:315.","journal-title":"Br J Haematol"},{"key":"447_CR5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","volume":"20","author":"BM Koffman","year":"1997","unstructured":"Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102.","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"447_CR6","first-page":"10","volume":"104","author":"J Anderson","year":"1996","unstructured":"Anderson J, Skansen-Saphir U, Sparrelid E, et al. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes\/macrophages. Clin Exp Immunol. 1996;104 Suppl 1:10\u201320.","journal-title":"Clin Exp Immunol"},{"key":"447_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000237689","volume":"114","author":"MCS Menezes","year":"1997","unstructured":"Menezes MCS, Benard G, Sato MN, et al. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol. 1997;114:323\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"447_CR8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/iai.58.5.1384-1390.1990","volume":"58","author":"T Shimozato","year":"1990","unstructured":"Shimozato T, Iwata M, Tamura N. Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun. 1990;58:1384.","journal-title":"Infect Immun"},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484.","journal-title":"Science"},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10134","volume":"475","author":"RM Anthony","year":"2011","unstructured":"Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110.","journal-title":"Nature"},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1011039216251","volume":"21","author":"M Gupta","year":"2001","unstructured":"Gupta M, Noel GJ, Schaefer M, et al. Cytokine modulation with immune \u03b3-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21:193\u20139.","journal-title":"J Clin Immunol"},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1172\/JCI116240","volume":"91","author":"S Takei","year":"1993","unstructured":"Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602\u20137.","journal-title":"J Clin Invest"},{"key":"447_CR13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","volume":"84","author":"P Aukrust","year":"1994","unstructured":"Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994;84:2136\u201343.","journal-title":"Blood"},{"key":"447_CR14","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.4049\/jimmunol.151.7.3460","volume":"151","author":"JC Kam","year":"1993","unstructured":"Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993;151:3460\u20136.","journal-title":"J Immunol"},{"key":"447_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0091-6749(99)70466-5","volume":"103","author":"JD Spahn","year":"1999","unstructured":"Spahn JD, Leung DYM, Chan MTS, et al. Mechanisms of glucocorticoid reduction in asthmatics treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999;103:421\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"447_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/clin.1997.4329","volume":"83","author":"JF Modiano","year":"1997","unstructured":"Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol. 1997;83:77\u201385.","journal-title":"Clin Immunol Immunopathol"},{"key":"447_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","volume":"92","author":"T Vassilev","year":"1993","unstructured":"Vassilev T, Gelin C, Kaveri SV. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIG). Clin Exp Immunol. 1993;92:369\u201372.","journal-title":"Clin Exp Immunol"},{"key":"447_CR18","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367:2015\u201325. This paper provides a thorough review of currently proposed mechanisms of action of IVIG.","journal-title":"N Engl J Med"},{"key":"447_CR19","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1084\/jem.184.6.2385","volume":"184","author":"D Sylvestre","year":"1996","unstructured":"Sylvestre D, Clynes R, Ma M. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med. 1996;184:2385\u201392.","journal-title":"J Exp Med"},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1073\/pnas.0807319106","volume":"106","author":"B Tackenberg","year":"2009","unstructured":"Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fc\u03b3 receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106:4788\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"447_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546\u201354.","journal-title":"N Engl J Med"},{"key":"447_CR22","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1097\/01.CCM.0000295426.37471.79","volume":"35","author":"K Werdan","year":"2007","unstructured":"Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35:2693.","journal-title":"Crit Care Med"},{"key":"447_CR23","volume":"9","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring 3rd JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;9, CD001090.","journal-title":"Cochrane Database Syst Rev"},{"key":"447_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/421089","volume":"39","author":"J Pildal","year":"2004","unstructured":"Pildal J, G\u00f8tzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38.","journal-title":"Clin Infect Dis"},{"key":"447_CR25","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1097\/01.CCM.0000295312.13466.1C","volume":"35","author":"KB Laupland","year":"2007","unstructured":"Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686.","journal-title":"Crit Care Med"},{"key":"447_CR26","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1097\/01.CCM.0000295263.12774.97","volume":"35","author":"KG Kreymann","year":"2007","unstructured":"Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677.","journal-title":"Crit Care Med"},{"key":"447_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/tropej\/fmi011","volume":"51","author":"A El-Nawawy","year":"2005","unstructured":"El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005;51:271.","journal-title":"J Trop Pediatr"},{"doi-asserted-by":"crossref","unstructured":"Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst. Rev. 2010. CD001239","key":"447_CR28","DOI":"10.1002\/14651858.CD001239.pub3"},{"key":"447_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1100441","volume":"365","author":"P Brocklehurst","year":"2011","unstructured":"INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365:1201. This large randomized, controlled trial provided definitive evidence for lack of benefit of IVIG for the treatment of neonatal sepsis.","journal-title":"N Engl J Med"},{"doi-asserted-by":"crossref","unstructured":"Que YA, Moreillon P. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell: Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 7th ed. Philadelphia: Churchill Livingstone, An Imprint of Elsevier; 2009: 2543-74","key":"447_CR30","DOI":"10.1016\/B978-0-443-06839-3.00195-8"},{"issue":"4","key":"447_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/infdis\/148.4.692","volume":"148","author":"JM Vergeront","year":"1983","unstructured":"Vergeront JM, Stolz SJ, Crass BA, et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis. 1983;148(4):692\u20138.","journal-title":"J Infect Dis"},{"issue":"5","key":"447_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/infdis\/151.5.883","volume":"151","author":"SJ Stolz","year":"1985","unstructured":"Stolz SJ, Davis JP, Vergeront JM, et al. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis. 1985;151(5):883\u20139.","journal-title":"J Infect Dis"},{"key":"447_CR33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s10156-007-0551-6","volume":"13","author":"C Yanagisawa","year":"2007","unstructured":"Yanagisawa C, Hanaki H, Natae T, et al. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother. 2007;13:368\u201372.","journal-title":"J Infect Chemother"},{"key":"447_CR34","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.4049\/jimmunol.156.8.3057","volume":"156","author":"A Norrby-Teglund","year":"1996","unstructured":"Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol. 1996;156:3057.","journal-title":"J Immunol"},{"key":"447_CR35","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1128\/iai.64.12.5395-5398.1996","volume":"64","author":"A Norrby-Teglund","year":"1996","unstructured":"Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun. 1996;64:5395.","journal-title":"Infect Immun"},{"key":"447_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1086\/381979","volume":"38","author":"J Darenberg","year":"2004","unstructured":"Darenberg J, S\u00f6derquist B, Normark BH, Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004;38:836.","journal-title":"Clin Infect Dis"},{"key":"447_CR37","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1001\/jama.1992.03480240077038","volume":"267","author":"W Barry","year":"1992","unstructured":"Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 1992;267:3315.","journal-title":"JAMA"},{"issue":"6","key":"447_CR38","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/clinids\/21.6.1469","volume":"21","author":"F Lamothe","year":"1995","unstructured":"Lamothe F, D\u2019Amico P, Ghosn P, et al. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis. 1995;21(6):1469\u201370.","journal-title":"Clin Infect Dis"},{"key":"447_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/515199","volume":"28","author":"R Kaul","year":"1999","unstructured":"Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2014a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28:800\u20137.","journal-title":"Clin Infect Dis"},{"key":"447_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/376630","volume":"37","author":"J Darenberg","year":"2003","unstructured":"Darenberg J, Ihendyane N, Sj\u00f6lin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333.","journal-title":"Clin Infect Dis"},{"key":"447_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1086\/606048","volume":"49","author":"SS Shah","year":"2009","unstructured":"Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369.","journal-title":"Clin Infect Dis"},{"key":"447_CR42","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1086\/507037","volume":"43","author":"B Schrage","year":"2006","unstructured":"Schrage B, Duan G, Yang LP, et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 2006;43:743.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"447_CR43","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1161\/01.CIR.92.6.1604","volume":"92","author":"H Takada","year":"1995","unstructured":"Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation. 1995;92(6):1604\u201311.","journal-title":"Circulation"},{"issue":"2","key":"447_CR44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3565(24)29273-9","volume":"299","author":"C Kishimoto","year":"2001","unstructured":"Kishimoto C, Takada H, Kawamata H, et al. Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines. J Pharmacol Exp Ther. 2001;299(2):645\u201351.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"447_CR45","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1161\/01.CIR.95.11.2476","volume":"95","author":"DM McNamara","year":"1997","unstructured":"McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997;95(11):2476\u20138.","journal-title":"Circulation"},{"key":"447_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/313929","volume":"31","author":"G Nigro","year":"2001","unstructured":"Nigro G, Bastianon V, Colloridi V, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocyte myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis. 2001;31:65\u20139.","journal-title":"Clin Infect Dis"},{"key":"447_CR47","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1253\/jcj.62.871","volume":"62","author":"Y Takeda","year":"1998","unstructured":"Takeda Y, Yasuda S, Miyazaki S, et al. High-dose immunoglobulin G therapy for fulminant myocarditis. Jpn Circ J. 1998;62:871\u20132.","journal-title":"Jpn Circ J"},{"key":"447_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2796.2002.00929.x","volume":"251","author":"A Tedeschi","year":"2002","unstructured":"Tedeschi A, Giannini S, Ciceri L, Massari FM. High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature. J Intern Med. 2002;251:169\u201373.","journal-title":"J Intern Med"},{"key":"447_CR49","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/01.CIR.103.18.2254","volume":"103","author":"DM McNamara","year":"2001","unstructured":"McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254\u20139.","journal-title":"Circulation"},{"key":"447_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/01.CIR.89.1.252","volume":"89","author":"NA Drucker","year":"1994","unstructured":"Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89:252.","journal-title":"Circulation"},{"doi-asserted-by":"crossref","unstructured":"Duvic M. Urticaria, drug hypersensitivity rashes, nodules and tumors, and atrophic diseases. In: Goldman: Goldman\u2019s Cecil medicine, 24th ed. Saunders, An Imprint of Elsevier; 2011: 2532-43","key":"447_CR51","DOI":"10.1016\/B978-1-4377-1604-7.00448-6"},{"key":"447_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490\u20133.","journal-title":"Science"},{"issue":"3","key":"447_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.1440-0960.1999.00347.x","volume":"40","author":"TG Phan","year":"1999","unstructured":"Phan TG, Wong RC, Crotty K, Aldestein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Aust J Dermatol. 1999;40(3):153\u20137.","journal-title":"Aust J Dermatol"},{"issue":"1","key":"447_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1046\/j.1365-2133.2000.03276.x","volume":"142","author":"S Magina","year":"2000","unstructured":"Magina S, Lisboa C, Goncalves E, et al. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol. 2000;142(1):191\u20132.","journal-title":"Br J Dermatol"},{"issue":"4","key":"447_CR55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1067\/mjd.2002.127249","volume":"47","author":"P Tristani-Firouzi","year":"2002","unstructured":"Tristani-Firouzi P, Peterson MJ, Saffle JR. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47(4):548\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"447_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archderm.139.1.85","volume":"139","author":"K Wolff","year":"2003","unstructured":"Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis: the uncertainty persist but the fog is dispersing. Arch Dermatol. 2003;139(1):85\u20136.","journal-title":"Arch Dermatol"},{"issue":"3","key":"447_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1590\/S0365-05962012000300022","volume":"87","author":"C Comparin","year":"2012","unstructured":"Comparin C, Hans Filho G, Takita LC, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87(3):477\u201381.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"447_CR58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1684\/ejd.2010.1077","volume":"20","author":"J Chen","year":"2010","unstructured":"Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743\u20137. doi:10.1684\/ejd.2010.1077.","journal-title":"Eur J Dermatol"},{"key":"447_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","volume":"58","author":"J Schneck","year":"2008","unstructured":"Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR60","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","volume":"33","author":"M Stella","year":"2007","unstructured":"Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452\u20139.","journal-title":"Burns"},{"issue":"10","key":"447_CR61","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","volume":"48","author":"Y Yang","year":"2009","unstructured":"Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48(10):1122\u20138. doi:10.1111\/j.1365-4632.2009.04166.x.","journal-title":"Int J Dermatol"},{"key":"447_CR62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/pgmj.2009.096206","volume":"86","author":"KK To","year":"2010","unstructured":"To KK, Wong SS, Li IW, et al. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad Med J. 2010;86:515\u201321.","journal-title":"Postgrad Med J"},{"key":"447_CR63","first-page":"521","volume":"58","author":"J Katz","year":"2009","unstructured":"Katz J, Hancock K, Veguilla V, et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morb Mortal Wkly Rep. 2009;58:521\u20134.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"8","key":"447_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599\u2013609.","journal-title":"Ann Intern Med"},{"key":"447_CR65","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMc070359","volume":"357","author":"B Zhou","year":"2007","unstructured":"Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1451.","journal-title":"N Engl J Med"},{"key":"447_CR66","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmii.2010.07.001","volume":"44","author":"JL Chong","year":"2011","unstructured":"Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect. 2011;44:319\u201322.","journal-title":"J Microbiol Immunol Infect"},{"key":"447_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/INF.0b013e3181f127be","volume":"30","author":"DK Hong","year":"2011","unstructured":"Hong DK, Tremoulet AH, Burns JC, et al. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza A virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J. 2011;30:67\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"447_CR68","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2141.2009.08016.x","volume":"148","author":"M Yunoki","year":"2010","unstructured":"Yunoki M, Kubota-Koketsu R, Urayama T, et al. Significant neutralizing activity of human immunoglobulin preparations against pandemic 2009 H1N1. Br J Haematol. 2010;148:953\u201355.","journal-title":"Br J Haematol"},{"key":"447_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1874276901206010008","volume":"6","author":"K Hagiwara","year":"2012","unstructured":"Hagiwara K, Kawami S, Kato-Mori Y, et al. Protective role of human intravenous immunoglobulin from influenza A virus infection in mice. Open Hemotol J. 2012;6:8\u201311.","journal-title":"Open Hemotol J"},{"key":"447_CR70","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1378\/chest.12-2907","volume":"144","author":"I Hung","year":"2013","unstructured":"Hung I, To K, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest. 2013;144:464\u201373.","journal-title":"Chest"},{"key":"447_CR71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1086\/650462","volume":"50","author":"CL Gordon","year":"2010","unstructured":"Gordon CL, Johnson PD, Permezel M, et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis. 2010;50:672\u20138.","journal-title":"Clin Infect Dis"},{"key":"447_CR72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/CVI.05518-11","volume":"19","author":"CL Gordon","year":"2012","unstructured":"Gordon CL, Holmes NE, Grayson ML, et al. Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin Vaccine Immunol. 2012;19:446\u20138.","journal-title":"Clin Vaccine Immunol"},{"key":"447_CR73","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/cid\/ciq082","volume":"52","author":"CL Gordon","year":"2011","unstructured":"Gordon CL, Langan K, Charles P, et al. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A (H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis. 2011;52:422\u20136.","journal-title":"Clin Infect Dis"},{"key":"447_CR74","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/j.1537-2995.2010.02651.x","volume":"50","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lee CK, Hung I, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50:1967\u201371.","journal-title":"Transfusion"},{"unstructured":"2002 Immune Deficiency Foundation patient survey. Available at: http:\/\/www.primaryimmune.org\/pid\/survey.htm. Accessed February 12, 2014.","key":"447_CR75"},{"key":"447_CR76","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525\u2013553.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"447_CR77","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1046\/j.1537-2995.1989.29890020437.x","volume":"29","author":"JD Kalbfleisch","year":"1989","unstructured":"Kalbfleisch JD, Lawless JF. Estimating the incubation time distribution and expected number of cases of transfusion-associated acquired immune deficiency syndrome. Transfusion. 1989;29(8):672.","journal-title":"Transfusion"},{"unstructured":"Centers for Disease Control. Hepatitis C FAQs for the Public. Available at: http:\/\/www.cdc.gov\/hepatitis\/c\/cfaq.htm#cFAQ31. Accessed May 8, 2014.","key":"447_CR78"},{"doi-asserted-by":"crossref","unstructured":"Yang H, Gregori L, Asher DM, et al. Risk assessment for transmission of variant Creutzfeldt-Jakob disease by transfusion of red blood cells in the United States. Transfusion. 2014 Apr 1","key":"447_CR79","DOI":"10.1111\/trf.12637"},{"issue":"11","key":"447_CR80","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1111\/j.1537-2995.2012.03637.x","volume":"52","author":"C Teljeur","year":"2012","unstructured":"Teljeur C, Flattery M, Harrington P, et al. Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland. Transfusion. 2012;52(11):2285\u201393.","journal-title":"Transfusion"},{"issue":"1","key":"447_CR81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1423-0410.2001.00056.x","volume":"81","author":"PK Correll","year":"2001","unstructured":"Correll PK, Law MG, Seed CR, et al. Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sang. 2001;81(1):6\u201311.","journal-title":"Vox Sang"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-014-0447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-014-0447-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-014-0447-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-014-0447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:58:10Z","timestamp":1744149490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-014-0447-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s11908-014-0447-4","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"type":"print","value":"1523-3847"},{"type":"electronic","value":"1534-3146"}],"subject":[],"published":{"date-parts":[[2014,11,12]]},"assertion":[{"value":"12 November 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"447"}}